Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00411398 · ClinicalTrials.gov registry record · Phase 3

A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder

A Phase 3 study, sponsored by State University of New York - Upstate Medical University.

Completed
Registry status
Phase 3
Development phase
15
Enrollment target

NCT00411398 is a Phase 3 study that has completed, run by State University of New York - Upstate Medical University. The registered enrollment target is 15 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00411398, a Phase 3 study, has completed, sponsored by State University of New York - Upstate Medical University.

COMPLETED
Registry status
Phase 3
Development phase
15 participants
Enrollment target

Study Summary

This study is being conducted to evaluate the safety and effectiveness of memantine Add-On treatment of patients who are currently taking an SNRI or SSRI and who remain anxious and symptomatic despite treatment. Secondary objectives of this study are: •-to evaluate if there is an improvement in disability levels following memantine dosing -to evaluate if there is an improvement in sleep quality following memantine dosing

Interventions

  • DRUG Namenda/Memantine

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2006-12
Est. Completion 2010-05
Phase Phase 3

What the Registry Record Tells You About NCT00411398

The ClinicalTrials.gov registry entry for NCT00411398 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York - Upstate Medical University, which has 113 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Namenda/Memantine is the first listed.

NCT00411398 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00411398 about?

NCT00411398 is a clinical study titled "A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder". This study is being conducted to evaluate the safety and effectiveness of memantine Add-On treatment of patients who are currently taking an SNRI or SSRI and who remain anxious and symptomatic despite treatment. Secondary objectives of this study are: •-to evaluate if there is an improvement in di...

What is the current status of trial NCT00411398?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 15 participants. The study started on 2006-12. Estimated completion is 2010-05.

What interventions are being tested in trial NCT00411398?

The interventions under investigation include: Namenda/Memantine (DRUG).

Who is sponsoring clinical trial NCT00411398?

This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.